Fibroblast growth factor receptors in breast cancer: Expression, downstream effects, and possible drug targets

M. Tenhagen, P. J. Van Diest, I. A. Ivanova, E. Van Der Wall, P. Van Der Groep

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer treatments are increasingly focusing on the molecular mechanisms underlying the oncogenic processes present in tumors of individual patients. Fibroblast growth factor receptors (FGFRs) are among the many molecules that are involved in oncogenesis and are currently under investigation for their potential as drug targets in breast cancer patients. These receptor tyrosine kinases play a role in several processes including proliferation, angiogenesis, and migration. Alterations in these basal processes can contribute to the development and progression of tumors. Among breast cancer patients, several subgroups have been shown to harbor genetic aberrations in FGFRs, including amplifications of FGFR1, FGFR2, and FGFR4 and mutations in FGFR2 and FGFR4. Here, we review in vitro and in vivo models that have partly elucidated the molecular implications of these different genetic aberrations, the resulting tumor characteristics, and the potential of FGFRs as therapeutic targets for breast cancer treatment.

Original languageEnglish (US)
Pages (from-to)R115-R129
JournalEndocrine-related cancer
Volume19
Issue number4
DOIs
StatePublished - Aug 2012

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Fingerprint Dive into the research topics of 'Fibroblast growth factor receptors in breast cancer: Expression, downstream effects, and possible drug targets'. Together they form a unique fingerprint.

Cite this